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Introduction
Human cytomegalovirus (CMV) is a widespread human
pathogen that has a minor clinical impact on healthy individuals,
but causes various organ diseases in immunosuppressed
patients and neural damage in fetuses infected in utero (1), and
remains present as a lifelong latent infection. However,
latently infected CMV is frequently activated in immunocom-
promised individuals such as patients with AIDS or organ
transplants, thereby causing severe morbidity and eventual
mortality (2–5). The mechanism of viral pathogenesis is still
not well understood. Symptomatic CMV infection has been
treated successfully with ganciclovir (GCV), but the appear-
ance of GCV-resistant viruses is a current problem in the treat-
ment of immunocompromised patients with CMV infection.
Although foscarnet (PFA) and cidofovir (CDV) have been
used for combined treatment with GCV and for the treatment
of GCV-resistant CMV, these treatments are not always
successful (6). New or alternative efficacious anti-CMV agents
need to be developed (7–10).
Several Kampo (Japanese herbal) medicines are widely used
in Japan and China as an effective medication against some
disorders of the human body. Sho-seiryu-to (TJ-19; Xiao-
Qing-Long-Tang in Chinese) showed potent anti-influenza
virus activity in nasal and bronchoalveolar cavities (11) and
showed potent antiviral activity against H1N1 and H3N2
subtypes of influenza A and influenza B virus in vivo (12).
Hochu-ekki-to (TJ-41; Bu-Zhong-Yi-Qi-Tang in Chinese) has
been reported to enhance killing activities of peritoneal
macrophages against infected Listeria monocytogenes (13)
and augment splenic natural killer (NK) cell cytotoxicity
against Meth-A sarcoma (14). Furthermore, TJ-41 induced the
accumulation and activation of NK cells and markedly reduced
the viral load of murine CMV in the spleen in the early phase
of infection (15). Juzen-taiho-to (TJ-48; Shi-Quan-Da-Bu-Tang
in Chinese) is reported to have a stimulatory effect on the
immune response (16,17) and phagocytosis (18). We studied
these three types of Kampo medicines for anti-CMV activity
in vitro. These three kampo medicines are shown to inhibit the
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derivative work this must be clearly indicated.cytopathic effects (CPE) on CMV-infected MRC-5 cells and
CMV replication.
Materials and Methods
Cells and Specimens
The Towne strain of human CMV was used throughout the
study, and has been described elsewhere (19). CMV was prop-
agated in MRC-5 cells, and the clarified supernatant was
stored in liquid nitrogen until use. Viral infectivity was titrated
by plaque assay (20).
Medical plants used for preparation of Kampo medicines,
TJ-19, TJ-41 and TJ-48, were kindly provided by Tsumura
Co., Ltd (Tokyo, Japan). Mixtures of many types of medicinal
herbs: for TJ-19, Pinelliae tuber (6 g), Ephedrae herba (3 g),
Schizandrae fructus (3 g), Cinnamonomi cortex (3 g), Paeoniae
radix (3 g), Asari herba cum radice (3 g), Glycyrrhizae radix
(3 g) and Zingiberis siccatum rhizoma (3 g); for TJ-41,
Ginseng radix (4 g), Actractylodis rhizoma (4 g), Astragali
radix (4 g), Angeliceae radix (3 g), Zizyphy fructus (2 g),
Bupleuri radix (2 g), Glycyrrhizae radix (1.5 g), Zingiberis
rhizoma (0.5 g), Cimicifuga rhizoma (1 g) and Aurantii nobilis
pericarpium (2 g); and for TJ-48, Astragali radix (3 g),
Cinnamonomi cortex (3 g), Relmanniae radix (3 g), Paeoniae
radix (3 g), Cnidii rhizoma (3 g), Actractylodis lancease
rhizoma (3 g), Angelicae radix (3 g), Ginseng radix (3 g),
Poriacocos hoelen (3 g) and Glycyrrhizae radix (1.5 g) were
added with water and extracts at 100 C over a period of 1 h.
The extracted solution was filtered and spray-dried to obtain a
dry extract powder (Tsumura Report). The blended powder
was dissolved in cell culture medium. The quality of these
herbs was controlled by the Japanese Pharmacopeia. These
extracts (TJ-19, TJ-41 and TJ-48) whose chemical patterns
were obtained by three-dimensional HPLC analysis, have been
reported previously (21–23).
Cell Culture
MRC-5 cells (24) were cultured in Dulbecco’s modified Eagle’s
minimal essential medium (DMEM) (Nissui Pharmaceutical
Co. Ltd, Tokyo) supplemented with 10% heat-inactivated fetal
calf serum (FCS; Z.L. Bocknek Laboratory, Ontario, Canada),
L-glutamine (0.3 mg/ml), gentamicin (50 mg/ml) and ampho-
tericin B (2.5 mg/ml). All cell cultures were maintained in a
humidified incubator at 37 C in 5% CO2/95% air.
Viral Production
When MRC-5 cells in 24-well plates (IWAKI Microplate,
IWAKI Glass Co., Funahashi, Japan) reached confluency, the
cells were inoculated with CMV at a multiplicity of infection
(m.o.i.) of 0.1. After adsorption for 1 h, the cells were added
with 1 ml of DMEM containing 2% FCS in the presence or
absence of various concentrations of Kampo medicine for the
indicated time intervals. Production of infectious virus was
titrated using a plaque assay (20).
Dot Blot Hybridization
The conditions used for dot blot hybridization were essentially
those described previously (25,26), and signals were detected
using ECL (enhanced chemiluminescence) direct nucleic acid
labeling and detection systems (Amersham Pharmacia
Biotech, Inc., NY) according to the manufacturer’s instruc-
tions. The amplified polymerase chan reaction (PCR) product
from the UL54 DNA polymerase gene region as previously
described was used as the hybridization probe (27).
Western Blot Analysis
The CMV-infected cell proteins were separated by
electrophoresis on a 10% sodium dodecyl sulfate (SDS)–-
polyacrylamide gel. Proteins were then transferred to a PVDF
membrane (Hybond-p, Amersham Pharmacia Biotech AB,
Uppsala, Sweden) using 20 mM Tris, 150 mM glycine, pH 8.3
in 20% methanol. Membranes were incubated for 1 h at room
temperature with the blocking reagent [5% skim milk, Tris-
buffered saline–0.5% Tween-20 pH 7.6 (TBS-T)], and then
incubated for 1 h at room temperature with primary antibody
(mouse monoclonal antibody specific for a structural late
antigen, 65 kDa, ViroStat, Portland, ME) diluted 1:2000 in
TBS-T. The membranes were washed three times in TBS-T
and incubated with peroxidase-conjugated second antibody
diluted 1:10 000 in TBS-T for 1 h at room temperature. After
washing three times in TBS-T, immune complexes were
detected by the ECL system (Amersham Pharmacia Biotech)
according to the manufacturer’s instructions.
Statistical Analysis
Data were analyzed using Student’s t-test.
Results
Kampo Medicines Decreased CMV Replication
The effects of three types of Kampo medicines upon replication
of CMV in MRC-5 cell cultures were analyzed. Figure 1 shows
a typical experiment to determine the growth of CMV in either
untreated or Kampo-treated cultures. MRC-5 cells infected with
CMV produced infectious CMV 3 days post-infection (d.p.i.),
with a titer increase of at least 6 d.p.i. We demonstrated a sig-
nificant decrease in viral production in cells treated with all
three types of Kampo medicines (P   0.05). Next, to examine
the dose-dependent effect of Kampo medicines on the replica-
tion of CMV, we determined the production of CMV in MRC-5
cells treated with various concentrations of Kampo medicines.
An inhibitory effect on CMV production was observed in cells
treated with at least 0.01  g/ml of all three types of Kampo
medicine (Fig. 1A, B and C). TJ-19 was the most effective herb
for the inhibition of CMV production among the three kinds of
Kampo medicines (Fig. 1A) (P   0.05). The virocidal effect of
TJ-19 was then examined after incubation of cell-free CMV
with various concentrations of TJ-19. The infectivity of cell-free
CMV was unchanged (Fig. 1D)
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MRC-5 Cells with Kampo Medicine
CMV inoculated onto monolayered MRC-5 cells [m.o.i. of 0.1
plaque-forming unit (p.f.u.)/cell] was allowed to adsorb for 1 h
at 37 C. The cultures were then washed twice and incubated
with or without TJ-19 (0.1 or 1  g/ml). At the indicated time
intervals (Fig. 2), cells were observed through a phase
difference microscope. We observed the reduction of CPE by
incubation with TJ-19 (Fig. 2C and G, and D and H), which
was characterized by the decrease of round cells. At 6 d.p.i.,
most of the cells showed rounding without TJ-19 (Fig. 2F).
In contrast, only a small percentage of cells treated with TJ-19
showed rounding at 3 d.p.i., while at 6 d.p.i., ~20% of these
cells showed rounding. There was very little rounding in most
of the cells treated with only TJ-19 and in the cells not infected
with CMV (Fig. 2A and E).
Inhibition of CMV DNA Replication with TJ-19
To evaluate the effect of TJ-19 on replication of CMV DNA,
CMV-infected MRC-5 cells were cultured in the presence or
absence of TJ-19 (1 or 0.01  g/ml), and the extracted DNA
was used to estimate the synthesis of CMV DNA by dot blot
eCAM 2004;1(3) 287
Figure 1. Infectious human CMV production in lung embryonic fibroblasts inhibited by three kinds of Kampo medicines. Sho-seiryu-to (A), Hochu-ekki-to
(B) and Juzen-taiho-to (C) inhibited infectious CMV production in a dose-dependent manner. MRC-5 cells were incubated with the indicated concentration of
each Kampo medicine after infection with CMV. The production of virus in culture supernatant was determined 3 and 6 days after the infection by using a plaque
assay. Data represent means   SE from three independent experiments. (D) Sho-seiryu-to at any concentration has no virocidal effect against cell-free CMV.
Cell-free CMV was incubated with the indicated concentration of Sho-seiryu-to. Virus titer was determined 5 days after incubation using a plaque assay. Data
represent means   SE from three independent experiments. *P   0.05, statistical significance compared with the untreated group 6 d.p.i. by the Student’s t-test.
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Dhybridization. As shown in Fig. 3, TJ-19 inhibited CMV DNA
replication in CMV-infected MRC-5 cells ~3-fold dose-
dependently, compared with that in the untreated cells.
Contrasting Effect of TJ-19 on CMV Protein Synthesis
To determine the molecular nature of the late protein found in
the TJ-19-treated cells, we examined the late protein synthe-
sized in MRC-5 cells by western blot analysis. As shown in
Fig. 4, the CMV 65 kDa late protein was synthesized in CMV-
infected MRC-5 cells (lane 2). In contrast, the amount of late
protein synthesis was reduced by treatment of the infected
cells with TJ-19 (Fig. 4, lane 3).
Discussion
We demonstrated the effect of Kampo medicines on the repli-
cation of human CMV in MRC-5 cells. These three Kampo
medicines were first studied for anti-human CMV activity in
MRC-5 cells and an inhibitory effect was observed even at
0.01  g/ml. These anti-CMV activities were demonstrated fur-
ther through plaque and gene expression assays. Yukawa et al.
(8) reported that hot water extracts of some traditional herbs
have been shown to have anti-CMV activity at 1–5  g/ml
in vitro. Commonly, the clinical daily treatment concentration
of these Kampo medicines is 7.5 g per adult human in Japan.
The concentration of the effective element Glycyrrhizae radix,
a major component herb of the three Kampo medicines, in
plasma remained at ~0.1  g/ml for at least 36 h after treatment
(Tsumura Report). These low concentrations are sufficient to
inhibit CMV replication in vitro. Although the inhibitory effect
on the growth of the host cells might reduce the production of
CMV virions, these three Kampo medicines did not inhibit the
growth of MRC-5 cells, i.e. no decrease in the number of cells
was observed in MRC-5 cells incubated for 5 days in the pre-
sence of Kampo medicine compared with those in the absence
of Kampo medicine (data not shown). It is of interest that, in
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Figure 2. Sho-seiryu-to decreased the degree
of cytopathic effects in CMV-infected MRC-5
cells. MRC-5 cells were incubated with either
Sho-seiryu-to or medium alone after infection
with CMV. The degree of cytopathic effects of
CMV-infected (B, C, D, F, G and H) or unin-
fected cells (A and  E) was observed 3 and
6 days after infection using a phase difference
microscope. Photomicrographs are 200 
original magnification.
Blotted DNA
1.0     0.33     0.11   µ µg
None
0.01 µg/ml
1.0   µg/ml
Sho-seiryu-to
1.0   µg/ml
CMV
+
 
 
 
 
 
 
 
 
+
 
 
 
 
 
 
 
 
 
+
 
 
 
 
 
 
 
 
|
Figure 3. Sho-seiryu-to inhibited the replication of CMV DNA. The cells
infected with CMV were incubated in the absence or presence of the indicated
concentration of Sho-seiryu-to. DNA was extracted 5 days after infection. Dot
blotting analysis was performed with serially 3-fold diluted DNA and detected
using the ECL direct nucleic acid detection system.
Figure 4. Sho-seiryu-to regulates protein expression of CMV-infected cells.
MRC-5 cells were incubated with or without Sho-seiryu-to (0.01  g/ml) after
infection with CMV. Proteins were prepared 5 days after infection. Western
blotting analysis was performed using antibody against late antigen (65 kDa).
Proteins after electrophoresis on an SDS–polyacrylamide gel were transferred
to a nylon membrane. Immunoblotting was detected by the ECL system.
12 3
Late antigen
(65 KDa)
Sho-seiryu-to − −+
CMV −+   +spite of the massive inhibition of viral replication and degree
of CPE, the percentage of viable cells in the presence of
Kampo medicines was unaltered when compared with
untreated control cultures.
Hossain et al. (15) reported that the oral administration of
TJ-41 increased the splenic and hepatic cellularities in murine
CMV-infected mice and induced the accumulation and activa-
tion of NK cells. This treatment markedly reduced the viral
load in the spleen but not in the liver at the early phase of
infection. These herbal medicines may thus play an important
role in the treatment of HIV-infected AIDS patients where
opportunistic human CMV infections are very common and
also tend to be severe. Kampo medicine was found to be safe
and has been used clinically in Japan and in many other
countries. Kampo medicines may thus be valuable as a 
co-therapeutic agent against latent CMV infection.
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